Company intelligence / Profile preview
HDAX Therapeutics
Toronto, Ontario, Canadahdaxtx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
HDAX is in lead optimization phase with demonstrated efficacy in animal models showing full disease reversal in chemotherapy-induced peripheral neuropathy (CIPN), Charcot Marie Tooth disease (CMT), and diet-induced obesity (DIO). Their compounds show single digit nanomolar to picomolar potency against HDAC6 with improved pharmacokinetics.
- Therapeutic areas
- OncologyEndocrinologyCardiovascularNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on HDAX Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HDAX Therapeutics.